Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vir Biotechnology, Inc. (VIR)
Price$11.39Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.62B | $1.10B | $76.4M | $8.1M | $10.7M | $2.7M |
| Gross profit | $68.5M | $73.4M | $83.4M | $1.47B | $1.03B | $76.4M | $8.1M | — | — |
| Gross margin | 99.96% | 98.86% | 96.79% | 90.94% | 93.99% | 100.00% | 100.00% | — | — |
| Research & development | $456.0M | $506.5M | $579.7M | $474.6M | $448.0M | $302.4M | $148.5M | $100.2M | $62.5M |
| Operating expenses | $547.9M | $661.4M | $770.5M | $782.7M | $674.7M | $373.3M | $186.1M | $129.4M | $84.2M |
| Operating income | −$479.3M | −$587.2M | −$684.3M | $833.1M | $420.8M | −$297.0M | −$178.0M | −$118.7M | −$81.5M |
| Operating margin | −699.18% | −791.27% | −794.04% | 51.56% | 38.41% | −388.88% | −2,199.72% | −1,112.60% | −3,009.49% |
| EBITDA | −$467.6M | −$572.6M | −$664.9M | $839.9M | $426.0M | −$292.6M | −$174.7M | −$117.1M | −$81.2M |
| EBITDA margin | −682.14% | −771.65% | −771.47% | 51.98% | 38.89% | −383.12% | −2,159.00% | −1,097.43% | −3,000.07% |
| Net income | −$438.0M | −$522.0M | −$615.1M | $515.8M | $528.6M | −$298.7M | −$174.7M | −$115.9M | −$69.9M |
| Net profit margin | −638.87% | −703.40% | −713.69% | 31.92% | 48.25% | −391.09% | −2,158.98% | −1,086.28% | −2,579.47% |
| Basic EPSper basic share | -$3.16 | -$3.83 | -$4.59 | $3.89 | $4.07 | -$2.51 | -$5.76 | -$15.12 | -$32.45 |
| Diluted EPSper diluted share | -$3.16 | -$3.83 | -$4.59 | $3.83 | $3.96 | -$2.51 | -$5.76 | -$15.12 | -$32.45 |
Owners
Reported shareholders
12.22%of listed shares
BlackRock, Inc.20.68M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 12.22%20.68M shares |
ARCH Venture Management, LLC | 7.50%12.69M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 6.79%11.5M shares |
SB INVESTMENT ADVISERS (UK) LTD | 6.47%10.95M shares |
STATE STREET CORP | 5.89%9.96M shares |
GSK plc | 5.05%8.55M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.78%6.39M shares |
Point72 Asset Management, L.P. | 3.35%5.67M shares |
SCANGOS GEORGE A | ≈2.25%3.81M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.98%3.35M shares |
DIMENSIONAL FUND ADVISORS LP | 1.84%3.12M shares |
ADAR1 Capital Management, LLC | 1.45%2.46M shares |
GOLDMAN SACHS GROUP INC | 1.40%2.37M shares |
FMR LLC | 1.37%2.32M shares |
MORGAN STANLEY | 1.31%2.21M shares |
Nuveen, LLC | 1.17%1.98M shares |
Pictet Asset Management Holding SA | 1.15%1.95M shares |
Boxer Capital Management, LLC | 1.10%1.87M shares |
NORTHERN TRUST CORP | 0.85%1.43M shares |
Hudson Bay Capital Management LP | 0.81%1.36M shares |
Percentages use 169.19M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Napolitano JanetDirector | SellCommon Stock | 3.2K | $9.45 | $30.2K | 21.2K |
| Jun 1, 2026Form 4 · 10b5-1 | Sabatini BrentSVP, Chief Accounting Officer | SellCommon Stock | 379 | $9.45 | $3.6K | 61.9K |
| May 1, 2026Form 4 · 10b5-1 | SATO VICKI LDirector | SellCommon Stock | 22.0K | $10.05 | $221.1K | 1.08M |
| Apr 6, 2026Form 4 · 10b5-1 | De Backer MariannePresident and CEO | SellCommon Stock | 72.6K | $9.16 | $664.6K | 948.1K |
| Apr 1, 2026Form 4 · 10b5-1 | SATO VICKI LDirector | SellCommon Stock | 22.0K | $9.07 | $199.5K | 1.10M |